Phaseline

Targets › CD93

CD93 (Complement component C1q receptor): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Cell surface receptor that plays a role in various physiological processes including inflammation, phagocytosis, and cell adhesion. Plays a role in phagocytosis and enhances the uptake of apoptotic cells and immune complexes by acting as a receptor for defense collagens including surfactant protein A/SFTPA1, C1q, and mannose-binding lectin (MBL2). (UniProt, Q9NPY3)

Open in Phaseline: the race on CD93, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
DynamiCure BiotechnologyDCSZ11
Monoclonal antibody targeting CD93
CD93Phase 1Advanced or Metastatic Solid TumorsDec 2026

Conditions

Advanced or Metastatic Solid Tumors (1)

Modalities

mixed (1)

Companies

DynamiCure Biotechnology (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.